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Abstract 
Conjunctivitis, keratoconjunctivitis, and corneal ulcers are common eye disorders frequently 
diagnosed in both humans and animals, and are currently treated by topical administration of 
eye drops containing anti-inflammatory and antibacterial agents. The current molecules often 
lack efficacy because infections in hypoxic tissue contain methicillin-resistant Staphylococcus 
aureus and Pseudomonas aeruginosa; thus, new products for the treatment of ocular pain and 
inflammation are needed. The use of ozone, a molecule stabilized for topical use as an ozonide, 
could be providential due to its anti-inflammatory and bactericidal activity in certain anterior 
segment pathologies, in addition to promoting tissue repair properties. Ozonated oils have 
the same properties as gaseous ozone and are well tolerated by tissues. In the present study 
the repair and regeneration effect of ozonated oil in liposomes plus hypromellose (Ozodrop®, 
FB Vision, Ascoli Piceno, Italy) instilled 3–4 times a day in external ocular spontaneous pathol-
ogies both in animals and humans are reported. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Ozone (O3) gas is a molecule consisting of three atoms of oxygen in a dynamically unstable 
structure due to the presence of mesomeric states [1]. Thanks to its great oxidative power, 
ozone has been widely recognized as one of the best bactericidal, antiviral, and antifungal 
agents [2].  
In spite of its oxidative effect, an adequate ozone dose can trigger several useful biochem-
ical mechanisms and reactivate the antioxidant system (i.e., catalase, superoxide dismutase, 
glutathione peroxidase, etc.) [3]. Furthermore, ozone has been used as a clinical therapeutic 
agent for chronic wounds, such as trophic ulcers, ischemic ulcers, and diabetic wounds. The 
beneficial effects of ozone on wound healing might be assumed to be due to the upregulation 
of platelet-derived growth factor, transforming growth factor-β, and vascular endothelial 
growth factor expressions, the decreased bacterial infection, ameliorated impaired dermal 
wound healing, or increased oxygen tension by ozone exposure in the wound area [2]. Ozone 
in the gaseous state is extremely reactive and not always suitable as a topical treatment. In 
saline solution, its concentration reduces quickly with a first-order kinetic and its half-life is 2 
h: this means that in about 24 h very little ozone will be left in the solution. Interestingly, in 
spite of its instability, the ozone molecule can be stabilized – for topical use – as an ozonide 
between the double bonds of a monounsaturated fatty acid such as oleic acid [4, 5]. Ozonated 
oil is now used topically for the treatment of wounds, anaerobic infections, herpetic infections 
(HSV I and II), trophic ulcers and burns, cellulitis, abscesses, anal fissures, decubitus ulcers 
(bed sores), fistulae, fungal diseases, furunculosis, gingivitis, and vulvovaginitis [6].  
The use of ozone in certain eye anterior segment pathologies could be providential due to 
its anti-inflammatory and bactericidal activity, in addition to promoting tissue repair proper-
ties. Unfortunately, ozonated oil is highly irritant for corneal tissue; thus, a specific formula-
tion has been recently developed for ophthalmic use, based on liposomal sunflower ozonated 
oil plus hypromellose (Ozodrop®, FB Vision, Ascoli Piceno, Italy), which is extremely biocom-
patible with the delicate ocular surface tissue. 
In our experience, this new liposomal ozonated oil formulation, specifically intended for 
ophthalmic use, was used to promote wound healing and treat some infective pathologies in 
common eye disorders encountered in both humans and animals. Inflammatory anterior seg-
ment diseases necessitating adequate anti-inflammatory therapy, such as conjunctivitis, ker-
atitis, keratoconjunctivitis sicca, and corneal ulcers, are the most common eye disorders en-
countered in animals [7] and share some symptoms with humans, such as redness, chemosis, 
and exudation. 
A topical dosage of one or two drops of collyrium every 4 h over 3–7 days is recom-
mended, even though multiple and frequent instillations are often required to achieve clinical 
resolution, and some patients tend to become noncompliant with frequent medications [7, 8]. 
The current agents are quite expensive and they often lack efficacy because infections in hy-
poxic tissue contain methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa; 
in some cases, they are inadequate and can cause unacceptable side effects. 
In particular, there is a need for new products for the treatment of ocular pain and inflam-
mation, such as during external ocular infections and inflammations, due to the related risk of 
blindness. The overuse of antibiotics in the treatment of infectious diseases, and the appear-
ance of multidrug-resistant bacterial strains, has driven research towards the study of antimi-
crobial agents from essential oils [9]. Ozonated oils have the same properties of gaseous 
ozone, are well tolerated by biological tissues (corneal tolerability is increased in a liposomal 
formulation), and their biological activities are related to oxygenated compounds [9]. They 
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are able to eliminate the pathogens by direct oxidation mediated by hydrogen peroxide, 
lipoperoxyde, and selective cytotoxicity on fast-dividing cells. This occurs through bacterial 
lysis and cell death, negative regulation on mitochondrial activity in bacteria, and disturbance 
of viral lithic enzymes, in superimposable manners compared to those of phagocytic cells of 
the immune system [10]. Moreover, ozone allows a “physiological” wound healing, minimizing 
the risk of keloidal scar and also the risk of haze in the cornea. 
In addition, ozone promotes cell adaptation to oxidative stress and attenuates pathophys-
iological events mediated by reactive oxygen species. Ozone oxidative preconditioning signif-
icantly decreased malondialdehyde levels and increased the activity of superoxide dismutase, 
glutathione peroxidase, and catalase. Serum interleukin-1β levels tend to decrease with ozone 
oxidative preconditioning [10]. Based on the many features and possible applications of 
ozone, the aim of the present study was a preliminary evaluation of repair and regeneration 
effect of ozonated oil in liposomes plus hypromellose (Ozodrop®) instilled 3–4 times a day in 
external ocular spontaneous pathologies in both animals and humans. 
Veterinary Case Reports 
Case 1 
A 26-year-old, neutered male, Italian saddle horse, was referred to the Veterinary Teach-
ing Hospital of the University of Camerino because of right eye exophthalmos due to 
retrobulbar neoformation (probably neoplasm/osteosarcoma) and recurrent conjunctivitis, 
which had been treated with topical antibiotic (tobramycin) and both topical and systemic 
NSAIDs (piroxicam plus flunixine meglumine) without any significant improvement. On the 
day of presentation the horse showed a normal left eye; regarding the right eye, the symptoms 
were blepharitis and blepharospasmus, edematous and hyperemic conjunctiva, and plenty of 
mucous ocular discharge (Fig. 1). The day after the beginning of the therapy, blepharospasmus 
disappeared, and a reduction in blepharitis and conjunctival edema was noted. Moreover, 
there was a slight reduction in ocular discharge. After 3 days of therapy blepharitis and 
conjunctivitis disappeared and after a week of therapy the eye became completely normal 
(Fig. 2) 
Case 2 
A 6-month-old male European short hair cat (Fig. 3) was affected by chronic conjunctivitis 
present from birth, which was unresponsive to the traditional antimicrobial and anti-inflam-
matory therapy. The day of presentation the cat showed marked conjunctival edema, espe-
cially in the right eye, reddening of the conjunctiva, and mucous discharge in both eyes. Con-
junctival bacteriological swabs revealed normal bacteria count in the right eye (20 CFU) and 
the presence of Staphylococcus spp. and Enterococcus spp.; an increased amount of Staphylo-
coccus spp. (140 CFU) in the left eye was detected. Therapy was consistent with instillation of 
one eye drop of collyrium in both eyes, twice a day until clinical and bacteriological resolution. 
After 3 days of therapy the conjunctival bacterial count became normal in both eyes (20 CFU) 
and Enterococcus spp. disappeared. After 10 days of therapy the conjunctival symptoms were 
no longer detectable (Fig. 4). 
Case 3 
A 3-year-old male English bulldog (Fig. 5) was referred to our department because of the 
presence of chronic keratitis in the right eye due to entropion of both eyelids. Because of other 
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problems not related to the presenting pathologies, it was not possible to operate on the dog 
immediately due to the high risk of general anesthesia and, in accordance with the owner, it 
was decided to begin topical therapy with instillation of one drop of collyrium twice a day until 
surgery. On the day of the presentation the dog showed keratitis, corneal edema, and deep 
and superficial neovascularization. Discomfort, pruritus, and ocular mucous discharge were 
also present. After 10 days of therapy, keratitis had almost disappeared, corneal edema was 
resolved, and neovascularization remained only with a single, small caliper vessel arising from 
the limbus at the level of the medial cantus (Fig. 6). Entropion and mucous discharge were still 
present. 
Human Case Reports 
Case 1 
A 33-year-old man with a history of improper use of contact lens, including continuous 
wear, presented himself at our department with left eye pain, redness, and photophobia for 2 
days. Correct distance visual acuity was 20/25. Slit-lamp examination revealed severe con-
junctival injection with ciliary flush and a large inferior-nasal corneal abrasion with a positive 
fluorescein eye stain test (Fig. 7). Intraocular pressures were within the normal limits. The 
anterior chamber was quiescent, and the pupil was round and reactive. Topical moxifloxacin 
hydrochloride 0.5% 3 times a day and Ozodrop® 4 times a day were prescribed. Three days 
later the patient was without any ocular discomfort and the examination showed a clear cor-
nea, good healing of the defect, and no sign of inflammation (Fig. 8). 
Case 2 
A 79-year-old woman presented herself to our department reporting eye pain and irrita-
tion, headache, photophobia, and ocular discharge in the right eye. The patient had undergone 
perforating keratoplasty 10 years previously and in the last 3 months she had been in follow-
up for band keratopathy complicated by an inferior corneal ulcer from the 5 o’clock to the 8 
o’clock positions in the same eye. Examination showed perilesional infiltrates and edema, 
staining at cobalt-blue filtered light (Fig. 9). Intraocular pressures were within the normal lim-
its. The anterior chamber was quiescent, and the pupil was round and reactive. A 7-day regi-
men of topic Ozodrop® 4 times a day was prescribed. Posttreatment evaluation revealed im-
provement of clinical signs with reduction of the infiltrate and the edema. Moreover, a partial 
healing of the ulcer with a residual corneal pooling using the cobalt blue filter was shown 
(Fig. 10). Regarding the related symptoms, only a slight photophobia remained. 
Case 3 
A 71-year-old man was referred to our department because of pain and blurry vision in 
the left eye, which were unresponsive to conventional eye drops. The patient had a history of 
previous HSV-related corneal ulcer 2 months previously. Correct distance visual acuity was 
1/20 with severe photophobia and glare. Examination showed a central, prominent disk-
shaped area of stromal keratitis (Fig. 11) with a round stromal infiltrate and corneal thinning. 
Furthermore, a central corneal ulcer positive with staining at cobalt-blue filtered light was 
highlighted. Intraocular pressures were within the normal limits. The anterior chamber was 
quiescent, and the pupil was round and reactive. After 10 days of therapy with Ozodrop® 4 
times a day, corneal involvement was more circumscribed (Fig. 12), signs of staining were 
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satisfactorily resolved, and there was significant reduction of photophobia and glare symp-
toms. 
Discussion 
Conjunctivitis in horses represents a therapeutic challenge because it requires different 
active principles to be administered, almost never present a single eye drop, and the horses 
tend to get uncooperative in a short time, so the veterinarian often has to resort to alternative 
methods of treatment (i.e., subpalpebral lavage systems). In this case of recurrent conjuncti-
vitis secondary to retrobulbar lesion, the ozone-based eye drops were effective in solving the 
problem. The frequency of 3 times daily was well tolerated by the animal that showed good 
compliance with the treatment and long-lasting therapy results. Conjunctivitis in cats repre-
sents a common problem and traditional therapy involves the use of topical antibiotics and 
NSAIDs, and in some cases even systemic. In this case the ozone-based eye drops were able to 
reduce the congestion of conjunctiva in 10 days of application. Moreover, after only 3 days of 
treatment Enterococcus spp. was no longer detected and the total bacteria count had de-
creased to levels considered normal in cats. Entropion represents a common problem in 
brachycephalic dogs and the cornea is often affected by entropion-related changes such as 
erosion/ulceration, inflammation, neovascularization, and pigmentation. Entropion manage-
ment is usually surgical and requires general anesthesia. In cases such as the present one, 
where surgery could not be quickly performed, ozone-based eye drops were able to reduce 
the discomfort of the dog and improve corneal health, despite the persistence of an underlying 
cause (mechanical clutch of the hairs of the lids on the cornea).  
Human microbial keratitis is an ophthalmic public health problem, being one of the lead-
ing causes of blindness and visual impairment with significant economic consequences all 
over the world. Risk factors such as wearing contact lenses, trauma, intraocular surgery, ocu-
lar surface disease, and systemic diseases may promote the microorganism adhesion and the 
infection. In recent years the increasing number of antibiotic-resistant bacteria has motivated 
prospective research towards the discovery of new antimicrobial strategies. The literature 
shows that collagen cross-linking (CXL) may be an alternative treatment for refractory cases 
of human HSV and bacterial keratitis. Reactive oxygen species produced by CXL can eliminate 
or suppress the proliferation of pathogens through the destruction of the nucleic acids [11]. 
Recent findings support that CXL could be an acceptable complementary method for the treat-
ment of infectious keratitis [12]. Due to its great oxidative power, the ozone molecule, stabi-
lized for topical use, can be a viable alternative and an easier approach. Our experience seems 
to confirm the safety and effectiveness of such therapy with no side effects.  
This preliminary in vivo study has demonstrated that ozone-based eye drops have an 
anti-inflammatory and bactericidal activity, in addition to promoting tissue repair. All of these 
beneficial and therapeutic effects are contained in a unique ocular preparation, reducing the 
risk of noncooperation of patients in receiving medications. Ozone-based eye drops are very 
attractive due to their versatility and to various potential uses in ophthalmology.  
In conclusion, from our preliminary results, ozone-based eye drops represent a valid and 
suitable alternative therapy for the management of external ocular pathologies in both ani-
mals and humans. Furthermore, given their antimicrobial properties, ozone-based eye drops 
could be used as an aid for the preparation for intra- and extraocular surgical procedures (i.e., 
cataract surgery or intravitreal injection). However, more studies are needed to confirm these 
data. 
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Fig. 1. Right eye of a 26-year-old horse before starting the treatment. Note blepharitis and blepharospas-
mus, edematous and hyperemic conjunctiva, and plenty of mucous ocular discharge. 
 
 
 
Fig. 2. Same eye of Figure 1 after 7 days of therapy. Normal eye. 
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Fig. 3. Right eye of a 6-month-old cat before starting the treatment. Note marked conjunctival edema, red-
dening of the conjunctiva, and mucous discharge. 
 
 
 
Fig. 4. Same eye of Figure 3 after 10 days of therapy. Normal eye, with mucous discharge still present. 
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Fig. 5. Right eye of a 3-year-old English bulldog before starting the treatment. Note entropion, mucous 
discharge, keratitis, corneal edema, and deep and superficial neovascularization. 
 
 
 
Fig. 6. Same eye of Figure 5 after 10 days of therapy. Corneal edema has resolved and neovascularization 
remains only with a single, small caliper vessel arising from the limbus at the level of the medial cantus. 
Entropion and mucous discharge are still present. 
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Fig. 7. Left eye of a 33-year-old man before starting the treatment. Note ciliary flush and large epithelial 
defect. 
 
 
 
Fig. 8. Same eye of Figure 7 after 3 days of therapy; the appearance is normal epithelium with no inflam-
matory signs. 
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Fig. 9. Right eye of a 79-year-old woman before starting the treatment. Note inferior corneal ulcer from the 
5 o’clock to the 8 o’clock positions. 
 
 
 
Fig. 10. Same eye of Figure 9 after 7 days of therapy. Partial healing of the ulcer with a residual corneal 
pooling. 
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Fig. 11. Left eye of a 71-year-old man before starting the treatment. Note stromal keratitis and corneal 
ulcer. 
 
 
 
Fig. 12. Same eye of Figure 11 after 10 days of therapy. Resolution of corneal ulcer with negative staining. 
 
